T achykinins are a family of structurally related peptides that were originally thought to be of neuronal origin. The pre-eminent member of this family is substance P, which was identified in 1931. Neurokinins A and B; endokinins A, B, C, and D; hemokinins; and others were subsequently identified. Tachykinin receptors (NK 1 , NK 2 , and NK 3 ) have also been identified. 1 Tachykinins are widely expressed in central and peripheral nervous systems and participate in neurotransmission. Substance P and neurokinin A are required to produce moderate to severe pain. 2 Over the past several years, a steadily increasing number of peripheral actions of tachykinins have been reported. Tachykinins function in airways, the gastrointestinal tract, and the urinary tract, and mediate neurogenic inflammation. 3 The elaboration of high concentrations of neurokinin B by the placenta has been linked to pre-eclampsia. 4 Since platelet dysfunction is associated with pre-eclampsia, Graham and colleagues addressed the possibility that platelets respond to tachykinins.
The results of their studies hold a number of surprises. First, platelets aggregated and secreted granules in response to substance P. The authors demonstrated that tachykinin receptors NK 1 (the preferred receptor for substance P) and NK 3 (the preferred receptor for neurokinin B) are present in human platelets. Antibodies directed at NK 1 impaired, but did not abrogate, platelet aggregation in response to substance P. Similarly, platelets from NK 1 null mouse showed only a modestly impaired response to substance P. Thus, NK 1 participates in substance P-induced platelet activation, but other receptors likely contribute as well. Another surprise was that NK 1 receptors are expressed in an activation-dependent manner. For example, stimulation with thrombin resulted in a 9-fold increase in NK 1 receptor surface expression. In addition, the authors found that platelets released a substance P-like peptide upon activation. The fact that platelets express tachykinin receptors and release a substance P-like peptide upon activation raised the possibility that tachykinins could behave in an autocrine/paracrine manner. To test this possibility, the authors stimulated platelets with submaximal concentrations of thrombin in the presence of antibodies directed at the NK 1 receptor. Under these conditions, anti-NK 1 receptor antibody inhibited thrombin-induced aggregation. Platelets from NK 1 receptor-deficient mice also displayed a modest impairment of thrombininduced aggregation induced by low thrombin concentrations. Taken together, these studies form strong evidence that tachykinins influence platelet function.
Historically, platelets have served as an easily accessible cell model for neurons. 5 The studies of Graham and colleagues reveal that platelets and neurons share a common set of stimulatory peptides and receptors. It is conceivable that under certain physiologic conditions tachykinins mediate cross talk between these 2 cell types. More plausibly, platelet tachykinins may participate as secondary agonists in hemostasis. The sharing of a common stimulatory axis has clinical implications. For example, do small molecule antagonists of tachykinin receptors, presently in clinical trials, represent bleeding risks? Might such therapeutics pose bleeding risks in combination with commonly used antiplatelet medications? These concerns await proof in a physiologic system that tachykinins function in hemostasis as they do in neurotransmission. ---------------------------------------------------------------------------------------------------------------- 
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The strength and persistence of identical signaling pathways determine the capacity of monocyte-derived DCs either to migrate to draining lymph nodes or to secrete locally inflammatory cytokines. D endritic cells are now perceived as sentinels to the immune system at the interface between innate and acquired immunity. They are empowered by their ability to recognize pathogens through Toll-like receptors (TLRs) and to alert both the innate arm of the immune system (through the release of inflammatory mediators at the site of infection) and the acquired arm (by eliciting a pathogenspecific immune response through naive Tcell priming following their migration to the draining lymph node). In a series of studies, Luft et al 1 have built a model suggesting that, depending on the signal encounter, dendritic cells (DCs), in particular DCs derived from monocytes, may acquire the capacity either to produce high levels of inflammatory cytokines or to migrate to the draining lymph node, these 2 capacities being mutually exclusive. The capacity of DCs to migrate to draining lymph nodes relies on their ability to respond to CC chemokine receptor 7 (CCR7) ligand chemokines, which drive their emigration out of the inflammatory site and their entry into For personal use only. by on April 16, 2008. www.bloodjournal.org From the lymph stream. 2 The authors have shown that monocyte-derived DCs activated by certain types of activation, such as tumor necrosis factor (TNF) ϩ prostaglandin E 2 (PGE 2 ), have a high propensity to respond to CCR7 ligands while producing low levels of inflammatory cytokines. In contrast, stronger stimuli, such as trimeric forms of CD40 ligand (CD40L), induce monocyte-derived DCs to secrete high levels of interleukin-12p70 (IL12p70) but prevent their response to CCR7 ligands. In a report in this issue, Luft and colleagues use monomeric or trimeric forms of CD40L or intact microbes applied during controlled time lapse to further show that the strength and persistence of identical signaling pathways determine the capacity of monocytederived DCs either to develop strong migratory ability toward CCR7 ligand (weak and transient signaling) or to secrete inflammatory cytokines (strong and persistent signaling). Indeed, they found that the strength and persistence of signaling induced by these different activators, as measured by the levels of extracellular signal-regulated kinase 1/2 (ERK1/2) and p38K phosphorylation and nuclear factor-B (NF-B) binding activity, were predictive determinants of the functional profile expressed by monocyte-derived DCs. ERK1/2 and p38K activation synergistically mediated cytokine secretion, whereas migration was enhanced by p38K activation but reduced by persistent ERK1/2 activity. The predominant migratory-type functional profile of CD1c ϩ peripheral blood DCs (PBDCs) can be explained according to their model by nonpersistent signaling induced in this population through CD40 ligation.
These observations are reminiscent of those by Rescigno and colleagues (Rotta et According to this model, persistent signaling may condition the local environment during pathogen invasion, when large amounts of IL-12p70 activate innate effector cells, such as natural killer (NK) cells. In contrast, DCs migrating out of epicenters of infection to draining lymph nodes will produce attenuated levels of cytokines more suitable for the priming and stimulation of antigen-specific T cells and avoiding bystander activation. s I matinib mesylate is an inhibitor of the protein tyrosine kinase domain associated with BCR-ABL, as well as those of the plateletderived growth factor (PDGF) and C-kit receptors, but is not generally thought to inhibit other members of the type II receptor kinase family. 1,2 However, since tyrosine kinases catalyze the transfer of phosphate from adenosine triphosphate (ATP) to tyrosine residues of substrate proteins, it is conceivable that other tyrosine kinases could be inhibited. Imatinib mesylate was originally selected as a 
